These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29851270)

  • 1. Vaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses.
    Ogasawara M; Miyashita M; Ota S
    Ther Apher Dial; 2018 Jun; 22(3):266-277. PubMed ID: 29851270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II Pilot Study of Wilms' Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer.
    Ogasawara M; Miyashita M; Yamagishi Y; Ota S
    Ther Apher Dial; 2019 Jun; 23(3):279-288. PubMed ID: 31033141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
    J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.
    Zhang W; Lu X; Cui P; Piao C; Xiao M; Liu X; Wang Y; Wu X; Liu J; Yang L
    Cancer Immunol Immunother; 2019 Jan; 68(1):121-130. PubMed ID: 30306202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy employing dendritic cell vaccination for patients with advanced or relapsed esophageal cancer.
    Ogasawara M; Miyashita M; Yamagishi Y; Ota S
    Ther Apher Dial; 2020 Oct; 24(5):482-491. PubMed ID: 32524770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility and Immune Response of WT1 Peptide Vaccination in Combination with OK-432 for Paediatric Solid Tumors.
    Hirabayashi K; Yanagisawa R; Saito S; Higuchi Y; Koya T; Sano K; Koido S; Okamoto M; Sugiyama H; Nakazawa Y; Shimodaira S
    Anticancer Res; 2018 Apr; 38(4):2227-2234. PubMed ID: 29599343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.
    Höltl L; Ramoner R; Zelle-Rieser C; Gander H; Putz T; Papesh C; Nussbaumer W; Falkensammer C; Bartsch G; Thurnher M
    Cancer Immunol Immunother; 2005 Jul; 54(7):663-70. PubMed ID: 15918076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.
    Laurell A; Lönnemark M; Brekkan E; Magnusson A; Tolf A; Wallgren AC; Andersson B; Adamson L; Kiessling R; Karlsson-Parra A
    J Immunother Cancer; 2017; 5():52. PubMed ID: 28642820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.
    Pandha HS; John RJ; Hutchinson J; James N; Whelan M; Corbishley C; Dalgleish AG
    BJU Int; 2004 Aug; 94(3):412-8. PubMed ID: 15291878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma.
    Leonhartsberger N; Ramoner R; Falkensammer C; Rahm A; Gander H; Höltl L; Thurnher M
    Cancer Immunol Immunother; 2012 Sep; 61(9):1407-13. PubMed ID: 22278360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma.
    Berntsen A; Geertsen PF; Svane IM
    Eur Urol; 2006 Jul; 50(1):34-43. PubMed ID: 16675096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
    Avigan DE; Vasir B; George DJ; Oh WK; Atkins MB; McDermott DF; Kantoff PW; Figlin RA; Vasconcelles MJ; Xu Y; Kufe D; Bukowski RM
    J Immunother; 2007 Oct; 30(7):749-61. PubMed ID: 17893567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma.
    Zhan HL; Gao X; Pu XY; Li W; Li ZJ; Zhou XF; Qiu JG
    Chin Med J (Engl); 2012 Nov; 125(21):3771-7. PubMed ID: 23106871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
    Kirner A; Mayer-Mokler A; Reinhardt C
    Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine therapy in patients with renal cell carcinoma.
    Van Poppel H; Joniau S; Van Gool SW
    Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma.
    Faiena I; Comin-Anduix B; Berent-Maoz B; Bot A; Zomorodian N; Sachdeva A; Said J; Cheung-Lau G; Pang J; Macabali M; Chodon T; Wang X; Cabrera P; Kaplan-Lefko P; Chamie K; Belldegrun AS; Pantuck AJ; Drakaki A
    J Immunother; 2020; 43(9):273-282. PubMed ID: 32925563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.
    Takahashi H; Okamoto M; Shimodaira S; Tsujitani S; Nagaya M; Ishidao T; Kishimoto J; Yonemitsu Y;
    Eur J Cancer; 2013 Mar; 49(4):852-9. PubMed ID: 23245331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines.
    Hanada S; Tsuruta T; Haraguchi K; Okamoto M; Sugiyama H; Koido S
    Hum Vaccin Immunother; 2019; 15(2):397-406. PubMed ID: 30230959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer.
    Lemoine FM; Cherai M; Giverne C; Dimitri D; Rosenzwajg M; Trebeden-Negre H; Chaput N; Barrou B; Thioun N; Gattegnio B; Selles F; Six A; Azar N; Lotz JP; Buzyn A; Sibony M; Delcourt A; Boyer O; Herson S; Klatzmann D; Lacave R
    Int J Oncol; 2009 Sep; 35(3):569-81. PubMed ID: 19639177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.